Skip to main content

Cancer Immunology, Immunotherapy OnlineFirst articles

25.01.2023 | Review

Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study

The global cancer burden is destined to increase in the next few years, and cancer represents a serious threat to public health worldwide. In fact, the rising proportion of adults and elderly patients are two important factors underlying the …

24.01.2023 | Research

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Lung cancer is the leading cause of cancer-related death in Europe and worldwide. Over the past decade, non-small cell lung cancer (NSCLC) without oncogenic addiction has undergone a major therapeutic paradigm shift with the development of immune …

23.01.2023 | Original Article

Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma

Immunotherapy using immune checkpoint inhibitors is associated with improved therapeutic effects in patients with lung cancer [ 1 , 2 ]; however, biomarkers for predicting responsiveness to immune checkpoint inhibitors remain unclear, aside from …

Open Access 23.01.2023 | Research

LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma

Radioresistance and immunosuppression remain the major obstacles in the anti-cancer treatments. This work studies the functions of sialic acid binding Ig like lectin 9 (SIGLEC9) and its related molecules in radioresistance and immunosuppression in …

Open Access 23.01.2023 | Research

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers

Chimeric antigen receptor (CAR)-engineered immune effector cells constitute a promising approach for adoptive cancer immunotherapy. Nevertheless, on-target/off-tumor toxicity and immune escape due to antigen loss represent considerable challenges.

Über diese Zeitschrift

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.

In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:

  • “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.
  • “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.

CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).







Cancer Immunology, Immunotherapy
Volume 43/1997 - Volume 72/2023
Springer Berlin Heidelberg
Elektronische ISSN
Print ISSN


Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.